person · Reporting owner

Alon Ruth

Disclosed activity across 5 companies

Tapewire entity: 57757
SEC CIK: 0001796386

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Alpha Tau Medical Ltd.DRTS · Entity 4784	Director	March 18, 2026	March 18, 2026
Chemomab Therapeutics Ltd.ANCN · Entity 7653	Director	January 01, 2020	January 02, 2020
Moringa Acquisition CorpMACA · Entity 110260	Director	February 16, 2021	March 02, 2021
Notable Labs, Ltd.VBLT · Entity 87239	Director	January 01, 2023	January 03, 2023
Silexion Therapeutics CorpSLXN · Entity 8506	Director	February 20, 2026	February 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Alpha Tau Medical Ltd.

Report date March 18, 2026 · Filed March 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	29,367	Reported balance Holding disclosure · report date 2026-03-18 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 29,367
Restricted Share UnitsSEC Table I · non-derivative	Direct	4,680	Reported balance Holding disclosure · report date 2026-03-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,680 F1: These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $10.92 · Expires 2032-03-21	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: These are options to acquire ordinary shares, which have fully vested as of the date hereof.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $7.19 · Expires 2032-03-21	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F2: These are options to acquire ordinary shares, which have fully vested as of the date hereof.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.28 · Expires 2033-03-09	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F2: These are options to acquire ordinary shares, which have fully vested as of the date hereof.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.98 · Expires 2034-03-07	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F2: These are options to acquire ordinary shares, which have fully vested as of the date hereof.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2035-01-22	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance Not disclosed F2: These are options to acquire ordinary shares, which have fully vested as of the date hereof.
OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.41 · Expires 2036-03-09	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-18 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance Not disclosed F3: These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: These ordinary shares represent restricted share units, which will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

F2: These are options to acquire ordinary shares, which have fully vested as of the date hereof.

F3: These are options to acquire ordinary shares, which options will vest in their entirety upon the earlier of: one year commencing from March 9, 2026 or the next Annual General Meeting of Shareholders, subject to the Reporting Person's continued service.

Chemomab Therapeutics Ltd.

Report date January 01, 2020 · Filed January 02, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2027-09-09	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-01-01 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F3: The exercise price was converted from New Israeli Shekel ("NIS") 9.10 using the Bank of Israel representative rate known on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise. F1: 1/4 of the options vest one year following the vesting commencement date of July 27, 2017, and 1/16 at the end of each calendar quarter thereafter, until fully vested.
Employee stock optionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2029-07-02	Direct	Not disclosed	Reported balance Holding disclosure · report date 2020-01-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: 1/3 of the options vest one year following the vesting commencement date of July 3, 2019, and 1/12 at the end of each calendar quarter thereafter, until fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: 1/4 of the options vest one year following the vesting commencement date of July 27, 2017, and 1/16 at the end of each calendar quarter thereafter, until fully vested.

F2: 1/3 of the options vest one year following the vesting commencement date of July 3, 2019, and 1/12 at the end of each calendar quarter thereafter, until fully vested.

F3: The exercise price was converted from New Israeli Shekel ("NIS") 9.10 using the Bank of Israel representative rate known on the date of grant. The actual exercise price is the NIS amount regardless of the exchange rate on the date of exercise.

Moringa Acquisition Corp

Report date February 16, 2021 · Filed March 02, 2021

This filing explicitly reported no securities owned.

Notable Labs, Ltd.

Report date January 01, 2023 · Filed January 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.71 · Expires 2037-03-21	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2038-01-02	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2038-12-17	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2039-12-19	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F2: These options were granted on 12/19/19 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 19, 2020 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2040-12-08	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F3: These options were granted on 12/08/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 8, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.31 · Expires 2041-12-07	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F4: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2042-01-02	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance Not disclosed F5: These options were granted on 01/02/22 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.

F2: These options were granted on 12/19/19 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 19, 2020 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.

F3: These options were granted on 12/08/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 8, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.

F4: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

F5: These options were granted on 01/02/22 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

Silexion Therapeutics Corp

Report date February 20, 2026 · Filed February 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	10,228	Reported balance After 2026-02-20 transaction · row 1 1 source row Row 1 · 2026-02-20 · Grant · Acquired 9,091 · Balance 10,228 F1: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of the Reporting Person's services as a director of the Issuer. The grant was approved by the Issuer's board of directors.
Stock Option (right to buy Ordinary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2036-02-12	Direct	10,685	Reported balance After 2026-02-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-20 · Grant · Acquired 10,685 · Balance 10,685 F2: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, in respect of the Reporting Person's services as a director of the Issuer, which grant was approved by the Issuer's board of directors. F3: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
Stock Option (right to buy Ordinary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2035-02-09	Direct	935	Reported balance Holding disclosure · report date 2026-02-20 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance 935 F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of the Reporting Person's services as a director of the Issuer. The grant was approved by the Issuer's board of directors.

F2: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, in respect of the Reporting Person's services as a director of the Issuer, which grant was approved by the Issuer's board of directors.

F3: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.

F4: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 20, 2026 Filed Feb 23, 2026 21:20 UTC	Silexion Therapeutics Corp SLXN · Entity 8506	GrantStock Option (right to buy Ordinary Shares) · Derivative	10,685	$0.00 Strike: $1.65	$0.00	Disclosure SEC source: 0001178913-26-000606 · zk2634429.xml · derivative · entry 2 Alon Ruth · CIK 0001796386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,685 Underlying: Ordinary Shares · 10,685 shares Expires 2036-02-12 F2 · kind: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, in respect of the Reporting Person's services as a director of the Issuer, which grant was approved by the Issuer's board of directors. F3 · derivative.exercise_date: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. F3 · derivative.expiration_date: The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. Read SEC document
February 20, 2026 Filed Feb 23, 2026 21:20 UTC	Silexion Therapeutics Corp SLXN · Entity 8506	GrantOrdinary Shares	9,091	$0.00	$0.00	Disclosure SEC source: 0001178913-26-000606 · zk2634429.xml · nonDerivative · entry 1 Alon Ruth · CIK 0001796386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,228 F1 · kind: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share ("ordinary shares"), in respect of the Reporting Person's services as a director of the Issuer. The grant was approved by the Issuer's board of directors. Read SEC document
February 09, 2025 Filed Dec 31, 2025 18:09 UTC	Silexion Therapeutics Corp SLXN · Entity 8506	GrantStock Option (right to buy ordinary shares) · Derivative	935	$0.00 Strike: $18.90	$0.00	Disclosure SEC source: 0001178913-25-004149 · zk2534154.xml · derivative · entry 3 Alon Ruth · CIK 0001796386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 935 Underlying: Ordinary Shares · 935 shares Expires 2035-02-09 F5 · derivative.exercise_price: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F5 · shares: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F5 · derivative.underlying_shares: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F5 · balance_after: The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025. Read SEC document
February 09, 2025 Filed Dec 31, 2025 18:09 UTC	Silexion Therapeutics Corp SLXN · Entity 8506	GrantOrdinary Shares	794	$0.00	$0.00	Disclosure SEC source: 0001178913-25-004149 · zk2534154.xml · nonDerivative · entry 1 Alon Ruth · CIK 0001796386 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 794 F1 · security: Represents ordinary shares underlying RSUs granted to the Reporting Person by the Issuer. The shares subject to this award vest in full on the first anniversary of the date of grant (i.e., on February 9, 2026), subject to the Reporting Person's continued service through such date. F1 · kind: Represents ordinary shares underlying RSUs granted to the Reporting Person by the Issuer. The shares subject to this award vest in full on the first anniversary of the date of grant (i.e., on February 9, 2026), subject to the Reporting Person's continued service through such date. F2 · shares: The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. F2 · balance_after: The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.